A Review of the Role of Genetic Factors in Guillain-Barré Syndrome

Overview

Journal J Mol Neurosci

Specialties Molecular Biology
Neurology

Date 2020 Oct 8

PMID 33029737

Citations 8

Authors

Amin Safa

Tahereh Azimi

Arezou Sayad

Mohammad Taheri

Soudeh Ghafouri-Fard

Affiliations

Soon will be listed here.

Abstract

Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy syndrome. Several genetic and environmental risk factors have been recognized for GBS. AS GBS is an immune-related disorder, abnormal functions of T cells, production of autoantibodies, and dysregulation of gene expression have been detected in GBS patients. Based on the critical role of human leukocyte antigen (HLA) in the regulation of immune responses, HLA alleles are among the mostly investigated loci in GBS. A number of polymorphisms within different genes, especially those linked with the regulation of immune responses, have been associated with GBS in different populations. Moreover, several studies have demonstrated abnormal expression of cytokine-coding genes in this disorder. Investigations in the animal model of GBS have also verified the aberrant regulation of Th1/Th2/Th17/Treg cytokines. In the current review, we describe the information about the role of these factors in GBS.

Citing Articles

Genetically predicted N-Acetyl-L-Alanine mediates the association between CD3 on activated and secreting Tregs and Guillain-Barre syndrome.

Lyu Q, Zhang L, Ding Y, Liu Z Front Neurosci. 2024; 18:1398653.

PMID: 39371607 PMC: 11450862. DOI: 10.3389/fnins.2024.1398653.

A retrospective analysis of the clinical profile and factors associated with mortality and poor hospital outcomes in adult Guillain-Barre syndrome patients.

Tewedaj Z, Huluka D, Kebede Y, Abebe A, Hussen M, Mohammed B Sci Rep. 2024; 14(1):15520.

PMID: 38969647 PMC: 11226644. DOI: 10.1038/s41598-024-65265-0.

Tumor Necrosis Factor-α, CD1A and CD1E Genetic Polymorphisms in Guillain-Barré Syndrome: A Study from India.

Chakraborty R, Verma R, Jain A, Garg R, Atam V, Malhotra H Ann Indian Acad Neurol. 2023; 26(2):167-173.

PMID: 37179667 PMC: 10171006. DOI: 10.4103/aian.aian_834_22.

HLA-A, HSPA5, IGFBP5 and PSMA2 Are Restriction Factors for Zika Virus Growth in Astrocytic Cells.

Sher A, Lao Y, Coombs K Viruses. 2023; 15(1).

PMID: 36680137 PMC: 9863221. DOI: 10.3390/v15010097.

Computational Identification of Guillain-Barré Syndrome-Related Genes by an mRNA Gene Expression Profile and a Protein-Protein Interaction Network.

Wang C, Liao S, Wang Y, Hu X, Xu J Front Mol Neurosci. 2022; 15:850209.

PMID: 35370550 PMC: 8968047. DOI: 10.3389/fnmol.2022.850209.

References

Bansil S, Mithen F, Cook S, Sheffet A, Rohowsky-Kochan C . Clinical correlation with serum-soluble interleukin-2 receptor levels in Guillain-Barré syndrome. Neurology. 1991; 41(8):1302-5. DOI: 10.1212/wnl.41.8.1302. View

Barzegar M, Jafari Rouhi A, Farhoudi M, Sardashti S . A report of a probable case of familial Guillain Barre syndrome. Ann Indian Acad Neurol. 2013; 15(4):299-302. PMC: 3548371. DOI: 10.4103/0972-2327.104341. View

Blum S, McCombe P . Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions. J Peripher Nerv Syst. 2014; 19(2):88-103. DOI: 10.1111/jns5.12074. View

Blum S, Reddel S, Spies J, McCombe P . Clinical features of patients with Guillain-Barré syndrome at seven hospitals on the East Coast of Australia. J Peripher Nerv Syst. 2013; 18(4):316-20. DOI: 10.1111/jns5.12045. View

Blum S, Csurhes P, Reddel S, Spies J, McCombe P . Killer immunoglobulin-like receptor and their HLA ligands in Guillain-Barré Syndrome. J Neuroimmunol. 2013; 267(1-2):92-6. DOI: 10.1016/j.jneuroim.2013.12.007. View

Blum S, Ji Y, Pennisi D, Li Z, Leo P, McCombe P . Genome-wide association study in Guillain-Barré syndrome. J Neuroimmunol. 2018; 323:109-114. DOI: 10.1016/j.jneuroim.2018.07.016. View

Breville G, Lascano A, Roux-Lombard P, Lalive P . IL-8 as a potential biomarker in Guillain-Barre Syndrome. Eur Cytokine Netw. 2020; 30(4):130-134. DOI: 10.1684/ecn.2019.0436. View

Caporale C, Papola F, Fioroni M, Aureli A, Giovannini A, Notturno F . Susceptibility to Guillain-Barré syndrome is associated to polymorphisms of CD1 genes. J Neuroimmunol. 2006; 177(1-2):112-8. DOI: 10.1016/j.jneuroim.2006.05.018. View

Chalon M, Sindic C, Laterre E . Serum and CSF levels of soluble interleukin-2 receptors in MS and other neurological diseases: a reappraisal. Acta Neurol Scand. 1993; 87(2):77-82. DOI: 10.1111/j.1600-0404.1993.tb04081.x. View

10.

Chang K, Chuang T, Lyu R, Ro L, Wu Y, Chang H . Identification of gene networks and pathways associated with Guillain-Barré syndrome. PLoS One. 2012; 7(1):e29506. PMC: 3254618. DOI: 10.1371/journal.pone.0029506. View

11.

Chang K, Lyu R, Ro Y, Chen Y, Ro L, Chang H . Increased serum concentrations of transforming growth factor-β1 (TGF-β1) in patients with Guillain-Barré syndrome. Clin Chim Acta. 2016; 461:8-13. DOI: 10.1016/j.cca.2016.07.013. View

12.

Creange A, Belec L, Clair B, Raphael J, Gherardi R . Circulating tumor necrosis factor (TNF)-alpha and soluble TNF-alpha receptors in patients with Guillain-Barré syndrome. J Neuroimmunol. 1996; 68(1-2):95-9. DOI: 10.1016/0165-5728(96)00075-6. View

13.

Creange A, Sharshar T, Planchenault T, Christov C, Poron F, Raphael J . Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barré syndrome. Neurology. 1999; 53(8):1683-91. DOI: 10.1212/wnl.53.8.1683. View

14.

Csurhes P, Sullivan A, Green K, Pender M, McCombe P . T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2005; 76(10):1431-9. PMC: 1739377. DOI: 10.1136/jnnp.2004.052282. View

15.

Dahle C, Ekerfelt C, Vrethem M, Samuelsson M, Ernerudh J . T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barré syndrome. J Neurol Sci. 1998; 153(1):54-60. DOI: 10.1016/s0022-510x(97)00178-0. View

16.

Dahle C, Kvarnstrom M, Ekerfelt C, Samuelsson M, Ernerudh J . Elevated number of cells secreting transforming growth factor beta in Guillain-Barré syndrome. APMIS. 2003; 111(12):1095-104. DOI: 10.1111/j.1600-0463.2003.apm1111204.x. View

17.

Das A, Khurshid S, Hayat S, Ahmed R, Islam Z . Glucocorticoid receptor gene polymorphisms in Guillain-Barré syndrome. J Neuroimmunol. 2020; 348:577388. DOI: 10.1016/j.jneuroim.2020.577388. View

18.

Debnath M, Nagappa M, Subbanna M, Sundaravadivel P, Talukdar P, Shivakumar V . Th17 pathway signatures in a large Indian cohort of Guillain Barré syndrome. J Neuroimmunol. 2018; 323:125-130. DOI: 10.1016/j.jneuroim.2018.08.001. View

19.

Debnath M, Nagappa M, Talukdar P, Subbanna M, Sundaravadivel P, Shivakumar V . Comprehensive cytokine profiling provides evidence for a multi-lineage Th responses in Guillain Barré Syndrome. Cytokine. 2018; 110:58-62. DOI: 10.1016/j.cyto.2018.04.026. View

20.

Demestre M, Parkin-Smith G, Petzold A, Pullen A . The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J Neuroimmunol. 2005; 159(1-2):146-54. DOI: 10.1016/j.jneuroim.2004.09.015. View